OKYO Pharma to Present at OIS XV in San Diego
OKYO Pharma (NASDAQ: OKYO) announced that CEO Gary S. Jacob, Ph.D. will present at OIS XV in San Diego on November 22, 2025 from 8:30–9:30 AM PT during the Anterior Innovation Showcase. The presentation will highlight OKYO's lead investigational drug urcosimod, a lipidated peptide for neuropathic corneal pain (NCP).
OKYO said recent positive top-line Phase 2 results support advancing to a 120-patient multi-center clinical trial, and the OIS XV session aims to engage clinicians, partners, and investors to accelerate development.
OKYO Pharma (NASDAQ: OKYO) ha annunciato che il CEO Gary S. Jacob, Ph.D. terrà una presentazione all'OIS XV a San Diego il 22 novembre 2025 dalle 8:30–9:30 AM PT durante il Anterior Innovation Showcase. La presentazione illustrerà il lead investigational drug urcosimod, un peptide lipidato per il dolore neuropatico oculare (NCP).
OKYO ha dichiarato che i recenti positivi risultati top-line di fase 2 supportano l'avanzamento verso uno studio clinico multicentrico di 120 pazienti, e la sessione OIS XV mira a coinvolgere medici, partner e investitori per accelerare lo sviluppo.
OKYO Pharma (NASDAQ: OKYO) anunció que el CEO Gary S. Jacob, Ph.D. presentará en OIS XV en San Diego el 22 de noviembre de 2025 de 8:30 a 9:30 a.m. PT durante el Anterior Innovation Showcase. La presentación destacará el fármaco en investigación líder de OKYO, urcosimod, un péptido lipídico para el dolor neuropático ocular (NCP).
OKYO indicó que recientes resultados positivos de la fase 2 a gran escala respaldan avanzar hacia un ensayo clínico multicéntrico de 120 pacientes, y la sesión de OIS XV tiene como objetivo involucrar a médicos, socios e inversores para acelerar el desarrollo.
OKYO Pharma(NASDAQ: OKYO)가 CEO Gary S. Jacob, Ph.D.가 산디에고에서 열리는 OIS XV의 2025년 11월 22일 오전 8:30–오전 9:30 PT 동안 Anterior Innovation Showcase에서 발표할 예정이라고 발표했습니다. 발표는 OKYO의 리드 연구개발 약물 urcosimod, 신경병성 각막 통증(NCP)을 위한 지질화된 펩타이드에 대해 조명할 것입니다.
OKYO는 최근 상위 라인의 양성 Phase 2 결과가 120명 다기관 임상시험으로의 진행을 뒷받침한다고 말했으며, OIS XV 세션은 임상의, 파트너, 투자자들을 참여시켜 개발을 가속화하는 것을 목표로 합니다.
OKYO Pharma (NASDAQ: OKYO) a annoncé que le PDG Gary S. Jacob, Ph.D. présentera lors de l'OIS XV à San Diego le 22 novembre 2025 de 8 h 30 à 9 h 30 PT pendant le Anterior Innovation Showcase. La présentation mettra en lumière le médicament expérimental phare de OKYO, urcosimod, un peptide lipidé pour la douleur neuropathique cornéenne (NCP).
OKYO a indiqué que les récents résultats positifs de la phase 2 soutiennent une progression vers un essai clinique multicentrique de 120 patients, et la séance OIS XV vise à réunir des cliniciens, partenaires et investisseurs pour accélérer le développement.
OKYO Pharma (NASDAQ: OKYO) kündigte an, dass CEO Gary S. Jacob, Ph.D. auf der OIS XV in San Diego am 22. November 2025 von 8:30–9:30 AM PT während des Anterior Innovation Showcase präsentieren wird. Die Präsentation wird urcosimod, ein lipidhaltiges Peptid zur neuropathischen Hornhaut-Schmerzen (NCP), als führendes Prüfpräparat von OKYO hervorheben.
OKYO sagte, dass jüngste positive Top-Line-Ergebnisse der Phase-2-Studie die Weiterentwicklung zu einer 120-Personen-Multicenter-Studie unterstützen, und die OIS XV-Sitzung zielt darauf ab, Kliniker, Partner und Investoren zu engagieren, um die Entwicklung zu beschleunigen.
OKYO Pharma (NASDAQ: OKYO) أعلنت أن الرئيس التنفيذي Gary S. Jacob, Ph.D. سيقدم في OIS XV في سان دييغو يوم 22 نوفمبر 2025 من 8:30–9:30 صباحاً بتوقيت المحيط الهادئ خلال عرض الابتكار الأمامي. ستسلط العرض الضوء على دواء OKYO التجريبي الرائد urcosimod، وهو ببتيد دهني لعلاج الألم العصبي القرني (NCP).
قالت OKYO إن نتائج المرحلة 2 الإيجابية الأخيرة تدعم الانتقال إلى تجربة سريرية متعددة المراكز تضم 120 مريضاً، وتهدف جلسة OIS XV إلى إشراك الأطباء والشركاء والمستثمرين لتسريع التطوير.
- None.
- None.
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, November 22, 2025, from 8:30-9:30 AM PT, as part of the "Anterior Innovation Showcase" session.
OIS XV, taking place November 21-22, 2025, at the San Diego Marriott Marquis & Marina in San Diego, California, is a premier annual event organized by Ophthalmology Innovation Source. The summit brings together leading innovators, investors, executives, and clinicians in the eye care field to foster unparalleled networking and deliver cutting-edge insights into ophthalmic innovation. With a focus on anterior and posterior segment advancements, the conference features panel discussions, company showcases, and one-on-one partnering meetings, attracting global stakeholders committed to advancing treatments for vision-threatening conditions.
Dr. Jacob's presentation will highlight OKYO's lead investigational drug candidate, urcosimod, a lipidated peptide designed to treat NCP, a major unmet medical need. Building on recent positive top-line results from a Phase 2 trial in NCP—announced earlier this year—OKYO is advancing toward a 120-patient multi-center clinical trial, underscoring the company's commitment to addressing unmet needs in this underserved market. Urcosimod demonstrated promising anti-inflammatory and pain-relieving effects in a previous Phase 2 clinical trial.
"We are thrilled to showcase our progress with urcosimod at OIS XV, a cornerstone event for ophthalmic innovation," said Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma. "The recent Phase 2 data on NCP patients, reinforces urcosimod's potential to transform the treatment landscape for neuropathic corneal pain that affects sufferers worldwide with no FDA-approved options. The OIS XV meeting will allow us to engage with key opinion leaders and potential partners to accelerate our development of urcosimod for patients who desperately need effective therapies."
About Neuropathic Corneal Pain (NCP)
NCP is a condition that causes severe eye pain and sensitivity of the eyes. The exact cause of NCP is unknown but is thought to result from nerve damage to corneal nerves combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients, and recently completed a Phase 2 trial.
For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
When will OKYO Pharma (OKYO) present at OIS XV and which session is it?
What will OKYO discuss about urcosimod at OIS XV for OKYO (NASDAQ: OKYO)?
What clinical plans did OKYO announce for urcosimod (OKYO)?
Where and when is OIS XV taking place that OKYO will attend?
Does OKYO claim urcosimod showed beneficial effects in earlier trials?
How could the OIS XV presentation affect OKYO shareholders (OKYO)?
